CONANTOKINS: NMDA RECEPTOR SUBTYPES AND EPILEPSY
锥豆素:NMDA 受体亚型与癫痫
基本信息
- 批准号:6610790
- 负责人:
- 金额:$ 21.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-01-01 至 2007-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The conantokin-like peptide superfamily is a distinctive group of Conus peptides. Conformational stability of the conantokin-like peptides is not achieved through multiple disulfide crosslinks, but rather by post-translational modification. Glutamate residues that are spaced every three or four amino acids are modified to gamma-carboxyglutamate (Gla); this motif would stabilize a helical conformation in the extracellular environment through chelation of Ca++. One branch of the conantokin-like superfamily comprises the only peptidic ligands known to be targeted to N-methyI-D-aspartate (NMDA) receptors. The broad focus of the proposed work is to identify the members of the conantokin-like peptide superfamily that are targeted to NMDA receptors, and to evaluate the subtype selectivity of peptides in the superfamily that do target NMDA receptors. Since several conantokins (e.g., conantokin-G and conantokin-R) have previously been shown to be potent anticonvulsants, we plan to correlate NMDA receptor subtype selectivity of an individual conantokin to the anticonvulsant efficacy observed. The goal is to understand the underlying mechanisms of the unusually favorable protective index afforded by the
conantokin peptides when tested in an animal model, the Fring's audiogenic seizure mouse. A
longer-term objective is a functional characterization of the branches of the conantokin-like peptide superfamily that do not target NMDA receptors.
contorkin -样肽超家族是一组独特的Conus肽。conantokin样肽的构象稳定性不是通过多重二硫交联实现的,而是通过翻译后修饰实现的。间隔三到四个氨基酸的谷氨酸残基被修饰为γ -羧谷氨酸(Gla);该基序通过螯合Ca++在细胞外环境中稳定螺旋构象。康托酮类超家族的一个分支包括已知的唯一针对n-甲基- d -天冬氨酸(NMDA)受体的肽配体。所提出的工作的广泛焦点是鉴定靶向NMDA受体的conantokin样肽超家族成员,并评估靶向NMDA受体的超家族中肽的亚型选择性。由于一些conantokin(例如,conantokin- g和conantokin- r)先前已被证明是有效的抗惊厥药,我们计划将单个conantokin的NMDA受体亚型选择性与观察到的抗惊厥疗效联系起来。我们的目标是了解由美国政府提供的异常有利的保护指数的潜在机制
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BALDOMERO M OLIVERA其他文献
BALDOMERO M OLIVERA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BALDOMERO M OLIVERA', 18)}}的其他基金
“Conus venom peptides and their molecular targets: Using pharmaconomics and neuroethology as a framework for discovery”
– 芋螺毒液肽及其分子靶标:使用药理学和神经行为学作为发现框架 –
- 批准号:
10592438 - 财政年份:2022
- 资助金额:
$ 21.08万 - 项目类别:
“Conus venom peptides and their molecular targets: Using pharmaconomics and neuroethology as a framework for discovery”
– 芋螺毒液肽及其分子靶标:使用药理学和神经行为学作为发现框架 –
- 批准号:
10346236 - 财政年份:2022
- 资助金额:
$ 21.08万 - 项目类别:
“Conus venom peptides and their molecular targets: Using pharmaconomics and neuroethology as a framework for discovery”
– 芋螺毒液肽及其分子靶标:使用药理学和神经行为学作为发现框架 –
- 批准号:
10798547 - 财政年份:2022
- 资助金额:
$ 21.08万 - 项目类别:
“Conus venom peptides and their molecular targets: Using pharmaconomics and neuroethology as a framework for discovery”
– 芋螺毒液肽及其分子靶标:使用药理学和神经行为学作为发现框架 –
- 批准号:
10810172 - 财政年份:2022
- 资助金额:
$ 21.08万 - 项目类别:
Life history-guided drug discovery from venomous marine snails
以生活史为指导的有毒海洋蜗牛药物发现
- 批准号:
10361532 - 财政年份:2018
- 资助金额:
$ 21.08万 - 项目类别:
Life history-guided drug discovery from venomous marine snails
以生活史为指导的有毒海洋蜗牛药物发现
- 批准号:
9896842 - 财政年份:2018
- 资助金额:
$ 21.08万 - 项目类别:
CONOTOXINS AND HOMERIC NICOTINIC ACETYLCHOLINE RECEPTORS
芋螺毒素和荷马烟碱乙酰胆碱受体
- 批准号:
6610794 - 财政年份:2003
- 资助金额:
$ 21.08万 - 项目类别:
相似海外基金
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
- 批准号:
10004277 - 财政年份:2020
- 资助金额:
$ 21.08万 - 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
- 批准号:
10475298 - 财政年份:2020
- 资助金额:
$ 21.08万 - 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
- 批准号:
10013749 - 财政年份:2020
- 资助金额:
$ 21.08万 - 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
- 批准号:
10693904 - 财政年份:2020
- 资助金额:
$ 21.08万 - 项目类别:
Study on how anticonvulsants affect car driving
抗惊厥药如何影响汽车驾驶的研究
- 批准号:
20K17977 - 财政年份:2020
- 资助金额:
$ 21.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
- 批准号:
10266034 - 财政年份:2020
- 资助金额:
$ 21.08万 - 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
- 批准号:
10475109 - 财政年份:2020
- 资助金额:
$ 21.08万 - 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
- 批准号:
10248384 - 财政年份:2020
- 资助金额:
$ 21.08万 - 项目类别:
Prevention of neuropathic pain by antidepressants and anticonvulsants: in vivo patch-clamp analysis
抗抑郁药和抗惊厥药预防神经性疼痛:体内膜片钳分析
- 批准号:
24592355 - 财政年份:2012
- 资助金额:
$ 21.08万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Anticonvulsants, ischemic seizures and regeneration in the immature brain
抗惊厥药、缺血性癫痫发作和未成熟大脑的再生
- 批准号:
8492175 - 财政年份:2009
- 资助金额:
$ 21.08万 - 项目类别:














{{item.name}}会员




